Is tirzepatide better than semaglutide for weight loss?

Appears under: Weight loss and GLP-1

The studies

• 5 Repeated evidence Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis.
  2025 · Obesity (Silver Spring, Md.) · 35,000 participants
• 4 Large controlled trial Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
  2024 · JAMA · 783 participants
• 4 Large controlled trial Tirzepatide Once Weekly for the Treatment of Obesity.
  2022 · The New England journal of medicine · 2,539 participants
• 5 Repeated evidence Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.
  2024 · Endocrine
• 5 Repeated evidence Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety.
  2024 · Obesity reviews : an official journal of the Internatio · 5,140 participants
• 4 Large controlled trial Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.
  2025 · The lancet. Diabetes & endocrinology · 413 participants · manufacturer helped fund this
• 5 Repeated evidence Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide.
  2026 · Journal of diabetes · 367 participants
• 4 Large controlled trial Tirzepatide and health-related quality of life in adults with obesity or overweight: Results from the SURMOUNT-3 phase 3 randomized trial.
  2025 · Diabetes, obesity & metabolism · 292 participants
• 4 Large controlled trial Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials.
  2025 · Clinical obesity · 1,438 participants · manufacturer helped fund this
• 5 Repeated evidence Exploring the Efficacy and Safety of Tirzepatide in Obesity Management and Cardiometabolic Risk Factors: A Comprehensive Systematic Review and Meta-Analysis.
  2025 · Clinical obesity · 6,257 participants
• 5 Repeated evidence Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.
  2026 · JAMA network open · 442 participants · manufacturer helped fund this
• 4 Large controlled trial Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.
  2026 · Nature medicine · 102 participants · manufacturer helped fund this
• 4 Large controlled trial Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1.
  2025 · Diabetes, obesity & metabolism · 1,545 participants · manufacturer helped fund this
• 4 Large controlled trial Analysis of Tirzepatide Acquisition Costs and Weight Reduction Outcomes in the United Kingdom: Insights from the SURMOUNT-1 Study.
  2025 · Advances in therapy · 2,539 participants · manufacturer helped fund this
• 4 Large controlled trial Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial.
  2026 · Annals of the rheumatic diseases · 2,539 participants
• 4 Large controlled trial Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials.
  2026 · Diabetes, obesity & metabolism · 2,384 participants · manufacturer helped fund this
• 4 Large controlled trial Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial.
  2026 · Current medical research and opinion · 750 participants